secwatch.observer — SEC 8-K summary
======================================

Issuer:     Curanex Pharmaceuticals Inc (CURX)
CIK:        0002025942
Form:       8-K
Filed at:   2026-05-14T13:15:35+00:00
Accession:  0001493152-26-022898
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curanex completes key Phyto-N milestones; plans Q4 2026 IND for ulcerative colitis
--------------------------------------------------------------------------------

- Completed GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling studies.
- 28-day dose-range finding toxicology study in rats and dogs showed no adverse findings at any dose.
- Expanded pipeline to include cancer cachexia; global market estimated at $2.54B in 2024.
- Cash and equivalents of ~$4.0M as of March 31, 2026, sufficient for near-term development activities.
- Targeting Q4 2026 IND submission for ulcerative colitis; Phase I trial to follow FDA review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/0001493152-26-022898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer